An animal experiment reported that FFBJRG ameliorates hepatic disease by reducing the serum collagen levels of LN, HA, and IV-C and downregulating TGF-β-Smad pathway fibroblast signal transduction (Yang et al., 2013). This evidence concerns the gene TGFB1 and liver disorder.